Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 5, 2000
Last updated: May 13, 2011
Last verified: April 2008

July 5, 2000
May 13, 2011
September 2001
April 2008   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00006010 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gemcitabine plus docetaxel in treating patients who have unresectable or metastatic liver cancer.


  • Assess the six-month overall survival of patients with unresectable or metastatic hepatocellular carcinoma treated with gemcitabine and docetaxel.
  • Determine tumor response and time to progression in this patient population treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Assess the pharmacokinetics of docetaxel in patients treated with this regimen.

OUTLINE: Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.

Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

PROJECTED ACCRUAL: A total of 22-40 patients will be accrued for this study within 1-2.5 years.

Phase 2
Primary Purpose: Treatment
Liver Cancer
  • Drug: docetaxel
  • Drug: gemcitabine hydrochloride
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
April 2008   (final data collection date for primary outcome measure)


  • Histologically confirmed unresectable or metastatic hepatocellular carcinoma not amenable to combined radiotherapy and chemotherapy or orthotopic liver transplantation
  • Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension as at least 20 mm
  • Evidence of disease progression by serial imaging or biochemical evidence of a rising alpha-fetoprotein by serial testing
  • No history of brain or other CNS metastases not amenable to local therapy

    • Locally treatable CNS lesions (i.e., lesions treatable with surgery or radiosurgery) allowed if no evidence of CNS progression for at least 4 weeks after completion of therapy



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10.0 g/dL


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST no greater than 2.5 times ULN


  • Creatinine no greater than 1.5 times ULN


  • No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior hypersensitivity reaction to taxanes or other drugs formulated with polysorbate 80
  • No grade 2 or greater peripheral neuropathy


Biologic therapy

  • At least 4 weeks since prior biologic therapy or immunotherapy
  • No concurrent immunotherapy


  • See Disease Characteristics
  • Prior chemotherapy (excluding gemcitabine) for radiosensitization allowed
  • At least 4 weeks since prior chemotherapy
  • At least 6 months since prior chemoembolization
  • No prior chemotherapy for metastatic disease
  • No other concurrent chemotherapy

Endocrine therapy

  • At least 4 weeks since prior hormonal therapy


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy
  • No prior radiotherapy to 25% or more of bone marrow
  • No concurrent radiotherapy


  • See Disease Characteristics
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
CDR0000068019, NCCTG-N0041
Not Provided
Not Provided
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Study Chair: Steven R. Alberts, MD Mayo Clinic
National Cancer Institute (NCI)
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP